Breaking News, Collaborations & Alliances

Cobra Bio, Karolinska Inst. to Develop COVID-19 Vaccine

OPENCORONA consortium awarded €3 million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cobra Biologics, an international contract development and manufacturing organization (CDMO) for biologics and pharmaceuticals, and the Karolinska Institutet, one of the world’s leading medical universities, have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic. Partners in the consortium also include Kar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters